8-KEarnings & ResultsExhibits & Filings

STRYKER CORP 8-K Report, Financial Results (Jan 26, 2016)

Filed January 26, 2016For Securities:SYK

Summary

Stryker Corporation (SYK) announced its fourth quarter and full year 2015 financial results on January 26, 2016. This 8-K filing primarily serves to attach the press release detailing these operational and financial outcomes. Investors should review the attached press release for specific details regarding revenue, earnings, and other key performance indicators for the periods ending December 31, 2015. This filing indicates the company is providing timely updates on its financial performance, which is crucial for assessing its current standing and future prospects.

Key Highlights

  • 1Stryker Corporation (SYK) filed an 8-K on January 26, 2016, to report its Q4 and Full Year 2015 financial results.
  • 2The 8-K filing references a press release dated January 26, 2016, as Exhibit 99.1.
  • 3This filing is a standard procedure for publicly traded companies to disseminate financial results.
  • 4Investors can find detailed performance metrics, including revenue and earnings, within the attached press release.
  • 5The event date for these results was January 25, 2016, with the filing occurring the following day.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially report and attach Stryker Corporation's fourth quarter and full year 2015 financial and operational results, as announced in their press release dated January 26, 2016.

The detailed financial results for the fourth quarter and full year 2015 are contained within the press release dated January 26, 2016, which is included as Exhibit 99.1 to this 8-K filing.

This 8-K filing primarily serves to attach the press release containing historical results. Any forward-looking statements, guidance, or outlook would be detailed within that press release. Investors should refer to the press release itself for such information.

Investors should look for key metrics such as total revenue, revenue by segment (e.g., Orthopaedics, MedSurg, Neurotechnology & Spine), net income, earnings per share (EPS), and any commentary on sales growth drivers and profitability trends for Q4 and the full year 2015.